Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study

FERRERO, Simone;GHIONE, PAOLA;
2016

95
7
1107
1114
link.springer.de/link/service/journals/00277/index.htm
Bendamustine; First-line therapy; Follicular lymphoma; Indolent lymphoma; R-CHOP; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Treatment Outcome; Vincristine; Hematology
Mondello, Patrizia; Steiner, Normann; Willenbacher, Wolfgang; Wasle, Ines; Zaja, Francesco; Zambello, Renato; Visentin, Andrea; Mauro, Endri; Ferrero, Simone; Ghione, Paola; Pitini, Vincenzo; Cuzzocrea, Salvatore; Mian, Michael
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1639875
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 23
social impact